| Title: |
A Comparison of Stockholm3, Serum Biomarkers, and Risk Calculators to Predict Prostate Cancer in a Racially and Ethnically Diverse Cohort: Evaluation of the Stockholm3 Multiethnic SEPTA Trial. |
| Authors: |
Lazarovich, Alon1 (AUTHOR) alon.lazarovich@gmail.com; Vigneswaran, Hari2,3 (AUTHOR) hari.vigneswaran@ki.se; Palsdottir, Thorgerdur2 (AUTHOR) thorgerdur.palsdottir@ki.se; Eklund, Martin2 (AUTHOR) martin.eklund@ki.se; Discacciati, Andrea2 (AUTHOR) andrea.discacciati@ki.se; Nordström, Tobias2 (AUTHOR) tobias.nordstrom@ki.se; Hubbard, Rebecca A.4 (AUTHOR) rebecca_hubbard@brown.edu; Perlis, Nathan5 (AUTHOR) nathan.perlis@uhn.ca; Abern, Michael R.3,6 (AUTHOR) michael.abern@duke.edu; Moreira, Daniel M.3 (AUTHOR) moreira@uic.edu; Yonover, Paul7 (AUTHOR) pyonover@uropartners.com; Chow, Alexander K.8 (AUTHOR) alexander_k_chow@rush.edu; Watts, Kara9 (AUTHOR) kwatts@montefiore.org; Liss, Michael A.10 (AUTHOR) liss@uthscsa.edu; Thoreson, Gregory R.11 (AUTHOR) gthoreson@gmail.com; Abreu, Andre L.12 (AUTHOR) andre.abreu@med.usc.edu; Sonn, Geoffrey A.13 (AUTHOR) gsonn@stanford.edu; Plym, Anna2 (AUTHOR) anna.plym@ki.se; Wiklund, Fredrik2 (AUTHOR) fredrik.wiklund@ki.se; Grönberg, Henrik2 (AUTHOR) henrik.gronberg@ki.se |
| Source: |
Journal of Urology. May2025, Vol. 214 Issue 5, p590-599. 10p. |
| Subject Terms: |
Disease risk factors; Prostate-specific antigen; Prostate biopsy; Tumor markers; Decision making |
| Abstract: |
Purpose: The purpose of this study was to compare performance of Stockholm3 in an external validation with commonly used prostate cancer biomarkers and risk calculators. Materials and Methods: SEPTA was a multicenter trial validating Stockholm3 in a racially/ethnically diverse population of men meeting local care guidelines for prostate biopsy (2019-2023). In total, 2115 (98%) men with complete data for risk calculators and biomarkers were included. The primary outcome was detection of Grade Group ≥ 2 (GG ≥ 2) cancer. Predictors included Stockholm3, free/total PSA ratio, PSA density, European Randomized Study of Screening for Prostate Cancer-4, Prostate Biopsy Collaborative Group, and Prostate Cancer Prevention Trial version 2 risk calculators. Performance characteristics were computed at clinically used thresholds for each risk score. ROC analysis, graphical calibration assessment, and decision curve analysis were performed. Results: Among 2115 men, median age was 63 years (IQR: 58-68), median PSA was 6.1 ng/mL (IQR: 4.5-9.0), 415 (20%) had a prior negative prostate biopsy, and 356 (17%) had an MRI performed before biopsy. There were 1200 (56.7%) benign biopsies performed, 307 (14.5%) GG1 cancers detected, and 608 (28.8%) GG ≥ 2 cancers detected. The Stockholm3 test had superior discrimination (all P |
| Database: |
Supplemental Index |